A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.

Trial Details

NCT ID
NCT06326411
Phase
PHASE1
Sponsor
Nested Therapeutics, Inc
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • NST-628
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • Westwood, Los Angeles, California, United States|34.05612,-118.43063
  • Denver, Colorado, United States|39.73915,-104.9847
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Tampa, Florida, United States|27.94752,-82.45843

Key Eligibility Criteria

  • Subjects are eligible to be included in the study only if all of the following criteria apply:
  • Subjects must be ≥18 years old (or of legal age of consent in the country in which the study is taking place) at the time of signing the informed c…
  • Subjects who have a histologically or cytologically documented metastatic or locally advanced solid tumor, for which standard of care (SoC) therapy…
  • Part A: Subjects with any solid tumor with genetic alteration of or evidence of tumor dependence upon the RAS/MAPK pathway (subject to additional r…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →